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Persistent Epstein-Barr virus (EBV) infection is primarily controlled by HLA class I-restricted memory cyto-
toxic T-cell (CTL) responses which can be reactivated in vitro by stimulation of peripheral blood lymphocytes
with autologous lymphoblastoid cell lines. During an investigation of a donor infected by both type A and type
B EBV, CTL specific for type B EBV were isolated. The CTL were found to recognize an epitope encoded by the
EBNA-6B gene. The minimal epitope sequence was identified as QNGALAINTF, corresponding to residues 213
to 222 in the EBNA-6B protein, and presentation of this epitope was shown to be via HLA B62 (B15). This is
the first report of the characterization of an epitope that is EBV type B specific. CTL recognizing sequences
common to type A and type B EBV were identified as well. A cross-reactive epitope recognized by these CTL
was encoded within the EBNA-6 gene of both type A and type B. This minimal sequence for this epitope was
LLDFVRFMGV (residues 284 to 293 in both types), and the epitope was restricted through HLA A*0201. This
second epitope sequence overlaps with a published EBV B44-restricted epitope (EENLLDFVRF). The impli-
cations of these findings are discussed with respect to the design and efficacy of epitope-based vaccines.
Epstein-Barr virus (EBV) is a gamma herpesvirus which
establishes a latent lifelong infection in the host following
acute infection (13, 14). While primary infection generally oc-
curs in childhood without significant morbidity, adolescents
and young adults may present with the symptoms of acute
infectious mononucleosis. The main feature of infectious
mononucleosis (IM) is a self-limiting lymphoproliferation in-
volving both T and B cells accompanied by clinical symptoms
such as fever and lymphadenopathy (44, 45).
Evidence for latent EBV infection includes the observation
that spontaneous lymphoblastoid cell lines (LCLs) which ex-
press EBV-encoded latent proteins can be regularly estab-
lished from healthy immune individuals after explantation of
either lymph node tissue (29) or fractionated B lymphocytes
(50). Although latent EBV infection is usually asymptomatic,
sequential studies have established that recrudescence of viral
replication in the oral cavity may result in release of infectious
virus (50). The exact site of persistence of the virus is uncer-
tain, but the available evidence suggests that small lymphocytes
in the circulation harbor the virus in a nonproductive episomal
state (20). Accordingly, in asymptomatic donors, EBV DNA is
detectable by sensitive PCR analysis in peripheral blood lym-
phocytes (PBL) expressing the B-cell marker CD19 (24, 47).
Two types of EBV (types A and B or types 1 and 2) are
distinguishable primarily on the basis of variation in the DNA
and protein sequences of the latent EBV-associated nuclear
antigens (referred to here as EBNA-2A, -3A, -4A, and -6A
from the type A virus and EBNA-2B, -3B, -4B, and -6B from
the type B virus) (8, 38, 40). Sequencing of the prototypical
isolates of type A and type B EBV (B95-8 and Ag-876, respec-
tively) in these regions revealed 53% amino acid homology
between EBNA-2A and EBNA-2B (8) and 72 to 84% homol-
ogy between EBNA-3A and -3B, EBNA-4A and -4B, and
EBNA-6A and -6B (38). Strain variation due to other DNA
alterations or deletions as well as these A-B type differences
have been defined at the protein (11) and the DNA (21, 22)
level and recombination between multiple infecting strains was
found to occur frequently in oral hairy leukoplakia lesions (48).
These variations offer an alternative means of categorizing
EBV isolates, but the primary distinction of type A and type B
is still useful. Type A EBV is more readily isolated from
healthy donors; type B EBV infections or dual infections with
both type A and type B have proven easier to detect in im-
munosuppressed or human immunodeficiency virus-infected
individuals (2, 39, 43). A higher incidence of type B infection
in some studies led to the suggestion that type B or dual
infections are, in fact, relatively common and that resident
type B virus levels increase during immunosuppression (2, 18,
43).
It appears that latent EBV infection is primarily controlled
by HLA class I-restricted memory cytotoxic T-cell (CTL) re-
sponses (reviewed in reference 16). These CTL responses can
be reactivated in vitro by stimulating lymphocytes from sero-
positive individuals with autologous LCLs which express and
present major histocompatibility complex class I- and class
II-restricted epitopes at the cell surface. Several of these
epitopes have been identified using target cells infected by
recombinant vaccinia virus constructs (15, 17, 27, 28). Epitopes
specific for type A EBV as well as cross-reactive epitopes
encoded by both type A and B EBV have been defined previ-
ously (16), but no epitopes specific for type B EBV have been
reported thus far. In the present study, the response of a donor
exposed to both type A and type B EBV was investigated and
an epitope specific for type B EBV as well as a new cross-
reactive epitope were identified.
* Corresponding author. Mailing address: Queensland Institute of
Medical Research, The Bancroft Centre, P.O. Royal Brisbane Hospi-
tal, Herston, Queensland, Australia 4029. Phone: 61-7-3362 0346. Fax:
61-7-3362 0106. Electronic mail address: bevK@qimr.edu.au.
8858
 o
n
 N
ovem
ber 5, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
MATERIALS AND METHODS
Lymphocyte donor.A 17-year-old individual (patient 1) who initially presented
with clinical and pathological (EBV immunoglobulin M positive) symptoms of
acute infectious mononucleosis was the subject of this study. Blood specimens
were obtained from this donor 18 months following primary infection, by which
time serology revealed the donor to be EBV immunoglobulin M negative, anti-
viral capsid antigen positive, and anti-EBNA positive. PCR analysis revealed the
presence of both type A and type B EBV in blood from donor patient 1. The
presence of both virus types was supported by the observations that both type A
and type B spontaneous cell lines grew out (although only the former, EW-spon,
was established in long-term culture), and regression analysis (26) indicated that
the donor had memory CTL activity to both virus types (data not shown).
Virus typing and detection. EBNA-2A and -2B primers were used in PCR as
previously described (18) to distinguish between type A and type B EBV in DNA
extracted from PBL.
Vaccinia virus constructs. Recombinant vaccinia virus constructs, encoding
EBNA-1, -2B, -4A, and -6A, the latent membrane proteins LMP1 and LMP2, the
lytic antigens BHRF1 and BZLF1, and the control vacc-TK2, have already been
described (17, 19, 28). Vacc-EBNA-3B and vacc-EBNA-6B (i.e., vaccinia virus
constructs encoding the type B sequences of EBNA-3 and EBNA-6, respectively)
were constructed from an EBV genomic library derived from purified viral
genomes of the prototype type B strain Ag-876 (42). The viral DNA was digested
with HindIII and ligated into the l-ZAP cloning system (Integrated Sciences).
An 11.07-kbp HindIIIE fragment encoding the EBNA-3B, -4B, and -6B open
reading frames (ORFs) was subcloned into the vector pUC19. A 2.6-kbp BamHI-
CEIII (Klenow-treated) fragment within the region containing the BERF1 ORF
of EBNA-3B (38) was isolated and ligated into a BamHI-HindII digest of
pBCB07. This vaccinia virus vector drives recombinant gene expression by the
7.5K vaccinia virus promoter (1). The EBNA-3B sequence encoded in the trans-
fer plasmid was inserted into the TK gene of vaccinia virus by transfection and
homologous recombination as described previously (1). A 4-kbp Eco47III-
HindIII fragment within the EBV HindIIIE region containing the BERF4 ORF
of EBNA-6B was isolated and ligated into a HindII-HindIII digest of pBCB07.
This was subsequently processed as for EBNA-3B. Integrity of the vacc-
EBNA-3B and -6B constructs was confirmed both by immunoblotting and DNA
sequencing (data not shown). The EBNA-3B construct encompassed the whole
of the EBNA-3B sequence (amino acids 1 to 925 [38]), and the EBNA-6B
construct encompassed the whole EBNA-6B sequence, excluding the first exon
(amino acids 100 to 1069 [38]).
Establishment of cell cultures. (i) B-cell cultures. LCLs were established from
patient 1 by exogenous transformation of PBL with QIMR-WIL virus (type A
[31]) and Ag-876 virus (type B). These LCLs were designated EW-Wil and EW
Ag-876. Spontaneous LCLs (i.e., autologous LCLs infected with the donor’s
endogenous virus strain and designated EW-spon) were established in the pres-
ence of cyclosporin (34). LCLs from other donors were transformed by QIMR-
WIL or IARC-BL74 virus (25) (type A isolates) or by Ag-876 or QIMR-GOR
virus (30) (type B isolates). Other lines used in this study include Burkitt lym-
phoma (BL) cell lines (Chep and Mutu) and the spontaneous line QIMR-WW2-
LCL (12, 35, 36). B-cell lines were maintained in RPMI 1640 with 10 to 20% fetal
calf serum (FCS).
(ii) T-cell cultures. Unfractionated PBL were separated on Ficoll-Paque
(Pharmacia, Uppsala, Sweden) and stimulated by incubation with gamma-irra-
diated (8,000 rads) autologous LCLs (either type A LCL, EW-Wil, or type B
LCL, EW-Ag-876; 2 3 106 cells per well in 2 ml of growth medium without
recombinant interleukin-2, responder-stimulator ratio, 50:1) (23). After 3 days,
the cultures were cloned in agarose (SeaPlaque; FMC Corp, Rockland, Maine)
and the colonies were harvested 3 to 5 days later. Once established, the T cells
were maintained in T-cell growth medium (RPMI 1640 supplemented with 15%
FCS, 30% MLA-144 supernatant [TIB-201; American Type Culture Collection,
Rockville, Md.], and recombinant interleukin 2, 20 U/ml) (37, 49). Since the
clonal nature of the T cells was not established, they are referred to in the text
as cultures rather than clones. The cultures were routinely maintained in either
24-well plates or tissue culture flasks and restimulated twice weekly with gamma-
irradiated (8,000 rads) autologous LCLs.
Bulk T-cell cultures were subcultured and maintained after 3 to 4 days, as for
T-cell colonies. Phytohemagglutinin (PHA) blasts were generated by stimulation
of PBL with PHA (CSL, Melbourne, Australia) and subcultured after 4 days in
T-cell growth medium. Cultures were regularly screened for mycoplasma con-
tamination and were consistently negative. Natural killer (NK) target line K562
was used in CTL assays.
Fluorescence-activated cell sorter (FACS) analysis. Three-color cytofluoro-
graphic analysis of T-cell cultures was performed by means of direct immuno-
fluorescence using labelled monoclonal antibodies specific for CD3 (tricolor
conjugated), CD4 (fluorescein conjugated), and CD8 (phycoerythrin conjugated)
(Becton Dickinson, San Jose, Calif.). The labelled cells were analyzed on a
FACScan (Becton Dickinson lysis II software).
Cytotoxicity assays. T cells were assayed in modified 5-h 51Cr release assays
(25). Briefly, target cells were labelled for 1 h with 0.5 to 1.0 mC of 51Cr, washed,
and resuspended at 105 cells per ml. Target cells (50 ml) were incubated with an
equal volume of effectors (effector-target or E-T ratio, generally 10:1) in 96-well
V-bottomed microtiter plates, centrifuged, and incubated at 378C for 5 h. After
centrifuging again, 25 ml of supernatant was harvested and dried onto 96-well
solid scintillation microtiter plates before the radioactivity was counted in a
Topcount Microplate Scintillation Counter (Packard Instrument Company, Me-
ridan, Conn.).
For determination of antigenic specificity, target cells were infected with vac-
cinia virus constructs (multiplicity of infection, approximately 10:1) and labelled
with 51Cr by a modification of the previously described procedure (15). Infection
and labelling occurred simultaneously for 2.5 h before the cells were washed and
used in CTL assays. In some instances target cells were pretreated in V-wells with
monoclonal antibodies to HLA class I (W6/32) or class II (L243) for 30 min at
room temperature before effector cells were added.
Limiting dilution cultures. Limiting dilution cultures were established by dis-
tributing PBL in 24 replicates at 23 104 cells per well in 96-well round-bottomed
microtiter plates. Doubling dilutions were made to a final concentration of 1.6 3
102 cells per well. Approximately 104 gamma-irradiated (8,000 rads) autologous
type B (EW-Ag-876) LCLs were added to each well as both feeder and stimu-
lator cells to a total volume of 100 ml. Cultures were fed on days 4 and 7 with 50
ml of T-cell growth medium and assayed on day 10 or later. The plates were
subcultured and maintained in T-cell growth medium and restimulated with
gamma-irradiated EW-Ag-876 LCLs. Assays were against either type A or type
B LCLs or peptide-coated PHA blasts or LCLs. Precursor frequencies were
determined by a modification of the method of maximum likelihood estimation
(10).
Assessment of peptide specific activity. For determination of the antigenic
specificity at the peptide level, a set of 20-mer overlapping peptides of EBNA-6B
(residues 100 to 1069 [38]) were prepared by using a kit and software distributed
by Chiron Mimotopes (Chiron Corporation, Sydney, Australia). Nine-mer and
10-mer overlapping peptides with unblocked C and N termini were manufactur-
ered by Chiron Mimotopes. Labelled target cells were preincubated with over-
lapping peptides in the 96-well trays for 30 to 60 min before effectors were added.
Alternatively, labelled targets were preincubated with a high concentration of
peptide (40 to 80 mg/ml) and then washed twice before being used in CTL assays.
The washing procedure removes the complication of bystander killing in the
latter type of experiments (5).
Depletion experiments. T-cell cultures were depleted of either CD41 or CD81
cells by pretreatment with saturating levels of OKT4 (mouse anti-CD4) or OKT8
(mouse anti-CD8) for 30 min on ice before being washed twice and incubated
with washed Dynabeads M450 (sheep anti-mouse immunoglobulin G-coated
beads; Dynal, A.S, Oslo, Norway) at 48C for 60 min with rotation. Beads and
adherent cells were removed magnetically, and the remaining cells were washed
once before use in a CTL assay or FACScan analysis.
RESULTS
Establishment of T-cell cultures for analysis. In order to
determine the specificity of CTLs from donor patient 1, PBL
were isolated and were stimulated by the addition of type A
(EW-Wil) or type B (EW-Ag-876) autologous LCLs for 3 days.
The cultures were cloned in agarose and colonies were se-
lected, cultured, and assayed for CTL activity toward type A
and type B cell lines and the NK target K562. An example of
seven reactive cultures is shown in Table 1. NK reactivity in
each case was low (,10%), and all but one culture (B7) was
primarily CD8 positive. All cultures recognized the type B
LCL, but three (B4, B5, and B7) were considered to be type B
specific, as lytic activity toward type B cells was much greater
than that toward type A cells. The remaining cultures showed
activity toward both type A and type B targets.
Identification of target antigens. To identify antigens recog-
nized by the CTL cultures, vaccinia virus constructs containing
EBV gene sequences (see Materials and Methods) were used
to infect autologous type A LCLs (EW-Wil) and used as tar-
gets in CTL assays. Three of the cultures (B6, B7, and B9)
showed no recognition of any of the gene sequences used. Four
cultures (A3, A9, B4, and B5) gave significant enhancement of
CTL activity when vacc-EBNA-6B-infected LCLs were com-
pared with control cells or vacc-TK2-infected target cells and
reacted poorly with the other EBV sequences (EBNA-1,
EBNA-2B, EBNA-3B, EBNA-4A, LMP1, LMP2, BZLF1, and
BHRF1). The specificities of cultures A3 and B5 were inves-
tigated further. This was achieved by assaying these cultures
with EW-Wil LCLs infected with either vacc-EBNA-6A or
vacc-EBNA-6B (Fig. 1). Culture B5 recognized target cells
infected with vacc-EBNA-6B but not with vacc-EBNA-6A.
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This culture also killed autologous type B LCLs (EW-Ag-876)
but not type A LCLs (EW-Wil). These results suggested that
culture B5 recognized a type B-specific epitope within EBNA-
6B. In contrast, the CTL activity of culture A3 against EW-Wil
increased following infection by either vacc-EBNA-3A or -3B,
indicating that culture A3 recognized a cross-reactive epitope
common to both EBNA-6A and EBNA-6B. Recognition of
EW-Wil cells infected with vacc-TK2 was as expected, as these
target LCLs expressed EBNA-6A.
Characterization of the type B-specific epitope. To deter-
mine the minimal amino acid sequence recognized by the type
B-specific culture B5, 20-mer peptides, which overlapped by 10
amino acids and encompassed the complete EBNA-6B second
exon amino acid sequence, were synthesized. Autologous PHA
blasts were preincubated with these peptides and used as tar-
gets with culture B5 in CTL assays. This culture recognized the
peptide containing the EBNA-6B residues 210 to 229 (FGC
QNGALAINTFSATVWIP). To further minimalize this epi-
tope, 9-mer and 10-mer overlapping peptides within this 20-
mer sequence were prepared. CTL assays identified the mini-
mal epitope as the 10-mer QNGALAINTF (residues 213 to
222; Fig. 2). None of the overlapping 9-mer sequences were
recognized. The corresponding peptide from the type A over-
lapping sequence (QNAARTLNTF) was not recognized by
this culture (data not shown), thus confirming the type B spec-
ificity of these T cells.
Once the minimally active epitope was identified, this pep-
tide was used to sensitize autologous LCLs for rapid identifi-
cation of subsequent CTL cultures. Of the additional cultures
that were type B epitope specific, B15 and B16 were expanded
from the limiting dilution assay wells and were studied along
with culture B5.
HLA restriction of the type B-specific epitope. As FACS
assays revealed that cultures recognizing the EBNA-6B-en-
coded sequence QNGALAINTF consisted of mixtures of
CD41, CD41CD81, and CD81 cells when assayed initially, the
possibility that the CTL activity was actually due to a CD41
component needed to be eliminated. To determine the lytically
active cell type, Dynabeads coated with anti-CD4 or anti-CD8
were used to deplete either CD41 or CD81 cells from the type
B-specific cultures B15 and B16. When samples of three dif-
ferent epitope-reactive cultures were tested, depletion of the
CD41 cells (which would have included the CD41CD81 com-
ponent) did not reduce the CTL activity, whereas depletion of
the CD81 cells completely abrogated the epitope-specific ac-
tivity (Fig. 3). Depletion was confirmed by FACS analysis.
Supporting the depletion data, inhibition of type B-specific
CTL activity of the mixed cultures was obtained by anti-class I
monoclonal antiserum but not by the anti-class II serum (Fig.
4). These depletion and inhibition experiments thus confirmed
that the epitope-specific CTLs were CD81 class I-restricted T
cells.
The restricting allele was identified by sensitizing LCLs, BL
cell lines, or PHA blasts, all with known HLA specificities, with
FIG. 1. Specificity of CTL cultures B5 and A3. EW-Wil (type A autologous LCL) was infected with vacc-EBNA-6A, vacc-EBNA-6B, or vacc-TK2 and used as a
target in a CTL assay; EW-Wil and EW-Ag-876 (type B autologous LCL) were used as control targets. E-T ratios: n, 10:1;^, 5:1; , 2.5:1.
TABLE 1. Selection of CTL cultures
Culture no.
Target cells (% lysis) FACS markers (%a positive)
EW-Wil, type A EW-Ag-876, type B K562, NK sensitive CD31 CD41 CD31 CD81 CD31 CD41 CD81 CD31
A3 34 17 8 98 0.5 85 2
A9 18 10 6 89 2 82 10
B4 7 17 4 93 2 70 0
B5 6 24 8 95 4 91 5
B6 19 32 9.5 80 2 66 7
B7 8 30 4 86 80 0 1
B9 17 8 4 87 0 96 0
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the type B epitope and using these as target cells in CTL
assays. The only target cells recognized by the QNGALAI
NTF-specific CTLs were those that were both HLA A*0201
and B62 (B15) positive. In contrast, targets that expressed
HLA A*0201 but not B62 and target cells that only shared A24
or B51 alleles with the donor were not lysed (Table 2). These
data indicated that the epitope was B62 (B15) restricted.
Characterization of the cross-reactive (type A-B-specific)
epitope. Culture A3, which was shown to lyse both type A and
type B targets, was assayed against autologous PHA blasts
sensitized with pools of overlapping 20-mer peptides derived
from the EBNA-6B sequence. Cells sensitized with the pool
containing 6 3 20-mer peptides encompassing residues 280 to
349 in EBNA-6B were recognized by this CTL culture. These
peptides were subsequently assayed individually, and the pep-
tide corresponding to residues 280 to 299 (TEENLLDFVRF
MGVMSSCNS) was identified as the active peptide. Nine-mer
and 10-mer overlapping peptides corresponding to this se-
quence were synthesized and used in CTL assays to minimalize
this epitope. The minimally active peptide sequence was iden-
tified as LLDFVRFMGV, corresponding to residues 284 to
293 common to both EBNA-6A and -6B sequences. This se-
quence overlaps with that of the B44-restricted epitope EEN
LLDFVRF (residues 281 to 290 of EBNA-6A and -6B [6]). It
should be noted that the minimal epitope for culture A3 was a
10-mer and that the 9-mer peptides were only reactive at high
concentrations (data not shown).
HLA restriction of the cross-reactive epitope. HLA restric-
tion analysis of the cross-reactive epitope was performed as
described for the type B epitope (Table 2). Culture A3 consis-
tently recognized cells bearing HLA A*0201 but not cells bear-
ing A24, B51, or B62. Furthermore, the CTL activity of this
culture was inhibited by anti-class I antibodies but not by anti-
class II antibodies (data not shown). Finally, the A3 minimal
epitope corresponds to the motif already identified for HLA
A*0201 restriction (32). It was therefore concluded that the epi-
tope LLDFVRFMGV (corresponding to residues 284 to 293 in
both EBNA-6A and EBNA-6B) was HLA class I A*0201 re-
stricted.
Incidence of type B and cross-reactive CTL responses. To
attempt to estimate the incidence of type B-specific and cross-
reactive CTL responses, CTL activity was measured in serially
diluted PBL samples stimulated with a feeder layer of irradi-
ated autologous type B LCLs. These were assayed for CTL
activity against type A and type B autologous LCLs after 10
days. The results indicated a higher incidence of T-cell precur-
sors recognizing type B cells alone than those recognizing type
A and type B cells. Following identification of the minimal
peptide sequences for the type B and cross-reactive epitopes,
the same cultures were assayed for epitope-specific frequency
by limiting dilution analysis. For the type B epitope (QNGA
LAINTF), a frequency of 1/16,400 was calculated, compared
with 1/304,900 for the cross-reactive epitope (LLDFVRFM
GV).
DISCUSSION
The identification of an EBV type B-specific epitope repre-
sents the first demonstration of a CTL epitope encoded within
a type B-specific region of the EBV genome. The epitope was
identified as QNGALAINTF, corresponding to residues 213 to
222 of EBNA-6B. This epitope was shown to be restricted
through HLA B62 (B15), although the subtype specificity has
yet to be determined. B62, which comprises at least five sub-
types, has recently been reclassified as part of the B15 family.
Motifs for one member of the B15 family (B*1501) have pre-
viously been published (32). F is commonly found in the last
anchor position (9 or 10), and Q or L are the preferred resi-
dues at position 2. For the new type B epitope, F is in the
anchor position, whereas Q is found at position 1. Interesting-
ly, the corresponding type A sequence for this peptide (QNA
ARTLNTF), which was nonreactive in CTL assays (data not
shown), also conformed to this motif, suggesting that it may
also be able to bind to B*1501. The differences between the
type A and type B epitope sequences reside at amino acids 3,
5, 6, and 7 and would be expected to affect CTL recognition,
because of T-cell receptor differences, rather than HLA bind-
ing, thus explaining the lack of recognition of the type A
peptide.
A cross-reactive epitope (LLDFVRFMGV) was also iden-
FIG. 2. Identification of the minimal epitope sequence recognized by type
B-specific CTL (B5). EW-Wil LCL was coated with 10-mer overlapping peptides
covering amino acids of EBNA-6B. These were used as targets for CTL culture
B5 in a CTL assay (E-T ratio, approximately 5:1).
FIG. 3. Recognition of type B-specific epitope by class I-restricted, CD8-
positive CTLs. Type B-specific CTL cultures (B15 and B16) were depleted of
either CD41 or CD81 T cells with Dynabeads coated with either anti-CD4 or
anti-CD8 antibodies. Depleted fractions as well as untreated CTLs were assayed
for activity toward EW-Ag-876 cells (n) and EW-C3 cells (noncytolytic autolo-
gous T cells) either unsensitized ( ) or sensitized (^) with specific peptide.
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tified. This represents a previously unrecognized EBV-en-
coded epitope. This epitope corresponds to residues 284 to 293
of both EBNA-6A and -6B and was shown to be restricted
through HLA A*0201. This epitope sequence fulfills the pub-
lished A*0201 motif requirements with L and V as anchor
residues at positions 2 and 10 (or positions 2 and 9 in 9-mer
epitopes) (reviewed in reference 32). F at position 7 may cor-
respond to F at position 6 in a number of previously identified
9-mer peptides restricted through A*0201. This epitope over-
laps with a previously described epitope, EENLLDFVRF, that
is B44 restricted (6). Overlapping epitopes have been de-
scribed recently within the lytic EBV protein BZLF1 (3) and in
other viral systems as well (33, 46). The occurrence of over-
lapping epitopes suggests that these regions of the proteins are
more likely to be exposed and presented by the major histo-
compatibility complex, perhaps because of their conforma-
tional positions within their respective proteins.
An interesting facet of this study was the detection of both
type A and type B EBV in the one donor by PCR of both PBL
and spontaneous cell lines. Because type A EBV is easy to
isolate, it has been thought to predominate in healthy donors.
However, the available evidence also indicates a high preva-
lence of type B in the community (2). It is not known whether
this donor was infected with both viruses initially or whether
dual infection was the result of initial infection with one type
and subsequent infection with the other. If the latter was the
case, then it suggests that immunological responses to the first
virus type would not be protective against infection with the
other virus type.
Mouse model systems have been used to dissect the immune
response of host animals infected by more than one virus
(reviewed in references 9 and 41). An extrapolation of these
models would suggest that eventually one type of EBV would
become dominant. It was found in this study that stimulation of
the donor’s PBL with type A transformants led to the gener-
ation of predominantly cross-reactive CTL, while stimulation
by type B transformants led to a predominantly type B re-
sponse (data not shown). The lack of type A-specific CTL may
eventually result in dominance of the type A virus in this
donor.
FIG. 4. Inhibition of type B-specific epitope recognition by anti-class I antibodies. Cells from EW-C3, a non-cytolytic autologous T-cell culture, were sensitized with
type B-specific peptide and used as targets for CTL culture B15 in the presence or absence of antibodies to class I and class II major histocompatibility complex antigens.
TABLE 2. HLA restriction of type B-specific and cross-reactive epitopes
Target cells
(transforming isolate) EBV type Class I allele
a
Result for CTLb
Type B specific Cross-reactive
2Pep 1Pep 2Pep 1Pep
EW-PHA blasts A2 A24 B51 B15 2 1 2 11
RM-LCL (QIMR-WIL) A A101 A2 B8 B15 2 1 2 11
LP-LCL (QIMR-WIL) A A2 A32 B35 B15 2 1 1, 2 11
PGP-LCL (IARC-BL74) A A1 A24 B8 B14 2 2 2 2
WW II-LCL (QIMR-WWII) A A11 A24 B18 B39 2 2 2 2
IM-LCL (QIMR-GOR) B A1 A11 B51 B8 2 NT 2 NT
SB-PHA blasts A201 A201 B35 B57 2 2 2 11
Chep (BL) A A2 A3 B7 2 2 2 2
Mutu (BL) A A1 A2 B45 2 2 2 1
TM-LCL (QIMR-WIL) A A11 A32 B35 B15 2 2 2 2
JAP-LCL (QIMR-WIL) A A2 A28 B8 B15 2 1 2 1
a Boldface items indicate HLA alleles shared with donor.
b 2Pep, without peptide; 1Pep, with peptide; 2, no recognition; 1, recognition; 11, strong recognition; 1,2, weak recognition; NT, not tested.
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Finally, it is important when considering the possibility of
vaccinating against EBV to recognize that it may be necessary
to vaccinate against both type A and type B. If a patient,
particularly a transplant patient at risk of EBV-related post-
transplant lymphoma (7), is vaccinated against type A but not
type B EBV, there may be an even greater risk of clinical
disease if the patient is subsequently infected with type B virus.
It is particularly important to consider EBV type B epitopes in
view of the finding that type B is commonly detected in immu-
nosuppressed individuals. Subunit vaccines against EBV are
currently being tested in clinical trials. In the long term, such
vaccines would ideally contain cross-protective specificities.
Defining type B and cross-reactive epitopes may allow devel-
opment of a vaccine that is more effective in terms of the range
of EBV specificities that are targeted and HLA types that are
covered by the vaccine.
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